Corvus Pharmaceuticals, Inc. (CRVS)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
As of 10:22AM EDT. Market open.
| Previous Close | 1.9100 |
| Open | 1.8100 |
| Bid | 1.3200 x 200 |
| Ask | 2.1200 x 200 |
| Day's Range | 1.4300 - 1.9400 |
| 52 Week Range | 1.0500 - 4.1900 |
| Volume | |
| Avg. Volume | 227,934 |
| Market Cap | 91.702M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5600 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.63 |
- Thomson Reuters StreetEvents
Q1 2024 Corvus Pharmaceuticals Inc Earnings Call
Q1 2024 Corvus Pharmaceuticals Inc Earnings Call
- GuruFocus.com
Corvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Explore key financial outcomes, strategic updates, and expert insights from Corvus Pharmaceuticals' first quarter of 2024 earnings call.
GlobeNewswireCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefined Deep Response Threshold Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuti
© 2024 Yahoo. All rights reserved.